Beaten-down biotech Clovis Oncology (CLVS +10%) is trying to reverse its lengthy down trend, albeit on average volume. Shares have lost over 80% of their value since late February.
Today, stockholder Citadel Advisors LLC disclosed a 7.0% stake of ~3.96M common shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.